NCT05687435

Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

CompletedPHASE4INTERVENTIONAL

Trial Details

Start: 2023-01-30Est. Completion: 2024-04-29

Enrollment target: 240 participants

Locations

Mei Han，Associate professor，Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China

Functional DyspepsiaIrritable Bowel Syndrome With Diarrhea

1. To conduct a multicenter, randomized controlled trial across four hospitals to evaluate the efficacy of Hewei Anchang…

Beijing, ChinaEst. completion Jun 30, 2028

Occasional ConstipationGastrointestinal HealthGut Microbiota Composition

The goal of this randomized blinded placebo-controlled clinical trial is to investigate the effect of low- and high-dose…

London, CanadaEst. completion Dec 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.